Type 2 diabetes mellitus is a growing problem with increasing prevalence among pediatric individuals in the US. VeroScience is currently studying the utility of Cycloset in the treatment of type 2 diabetes mellitus among pediatric patients.
Creators of Cycloset®*, the first and only FDA approved sympatholytic dopamine D2 receptor agonist for the treatment of type 2 diabetes.
*See full prescribing info
Type 2 diabetes mellitus is a growing problem with increasing prevalence among pediatric individuals in the US. VeroScience is currently studying the utility of Cycloset in the treatment of type 2 diabetes mellitus among pediatric patients.